Relationship between expression of vascular endothelial growth factor and cervical lymph node metastasis in papillary thyroid cancer: A meta-analysis

Abstract

The aim of the present study was to examine the relationship between the protein expression of vascular endothelial growth factor (VEGF) and lymph node metastasis (LNM) in papillary thyroid cancer (PTC). VEGF-related articles that had been published until August 2016 were searched from the PubMed, EMBASE, and MEDLINE to identify the risk factors of LNM in PTC. RevMan 5.3 software was used for the meta-analysis. Finally, 9 articles met the inclusion criteria and were included in our meta-analysis. LNM was found to be present in 176 of 318 patients (57.8%) with high VEGF expression and in 71 of 159 patients (47.0%) with low VEGF expression. The overall OR was 2.81 (95% confidence interval, 1.49–5.29). LNM occurred more frequently in patients with high VEGF expression than in those with low VEGF expression (P=0.001). Heterogeneity was markedly decreased in the subgroup analyses of LNM in terms of the patients’ country of origin and the detection methods. Our meta- analysis concluded that the VEGF protein expression is associated with LNM in PTC.

Keywords

vascular endothelial growth factor / cervical lymph node metastasis / papillary thyroid cancer / meta-analysis

References

[1] XingM. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer, 2013, 13(3): 184-199 PMID: 23429735 PMCID: 3791171

[2] WuQ, ZhangYM, SunS. Clinical and sonographic assessment of cervical lymph node metastasis in papillary thyroid carcinoma. J Huazhong Univ Sci Technol Med Sci, 2016, 36(6): 823-827 PMID: 27924514

[3] DaviesL, WelchHG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg, 2014, 140(4): 317-322 PMID: 24557566

[4] ChenW, ZhengR, BaadePD, et al. . Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132 PMID: 26808342

[5] ColonnaM, UhryZ, GuizardAV, et al. . Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol, 2015, 39(4): 511-518 PMID: 26003877

[6] ChenAY, JemalA, WardEM, et al. . Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer, 2009, 115(16): 3801-3807 PMID: 19598221

[7] LiuZ, WangL, YiP, et al. . Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis. Int J Clin Exp Pathol, 2014, 7(3): 932-937 PMID: 24696711 PMCID: 3971295

[8] YuXM, LoCY, ChanWF, et al. . Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res, 2005, 11(22): 8063-8069 PMID: 16299237

[9] AlitaloK, CarmelietP. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell, 2002, 1(3): 219-227 PMID: 12086857

[10] JebreelA, EnglandJ, BedfordK, et al. . Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol, 2007, 88(4): 271-277 PMID: 17696908 PMCID: 2517322

[11] FolkmanJ. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 1995, 333(26): 1757-1763 PMID: 7491141

[12] KleinM, VignaudJM, HennequinV, et al. . Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab, 2001, 86(2): 656-658 PMID: 11158026

[13] LennardCM, PatelA, WilsonJ, et al. . Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery, 2001, 129(5): 552-558 PMID: 11331447

[14] KimBH, LeeCH, KimSJ, et al. . Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy. Thyroid, 2013, 23(11): 1431-1436 PMID: 23510334 PMCID: 3822372

[15] ErdemH, GundogduC, SipalS, et al. . Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol, 2011, 90(3): 312-317 PMID: 21335003

[16] LiY, LiL, LiQ, et al. . Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer. Exp Ther Med, 2015, 9(6): 2195-2201 PMID: 26136959 PMCID: 4473334

[17] LiJ, TengL, JiangH. Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma. Asia Pac J Clin Oncol, 2014, 10(2): 149-152 PMID: 23718885

[18] TianX, CongM, ZhouW, et al. . Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res, 2008, 36(4): 699-703 PMID: 18652765

[19] LeeSH, LeeSJ, JinSM, et al. . Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clin Exp Otorhinolaryngol, 2012, 5(3): 150-155 PMID: 22977712 PMCID: 3437416

[20] YasuokaH, NakamuraY, ZuoH, et al. . VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol, 2005, 18(8): 1127-1133 PMID: 15803188

[21] WangY, HuaQ. Clinical significance of HIF-1 alpha, VEGF and VEGF-C expression in papillary thyroid carcinoma. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (Chinese), 2007, 21(5): 204-206

[22] ZhaoQ, MingJ, LiuC, et al. . Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol, 2013, 20(3): 746-752 PMID: 22972508

[23] LiuZ, XunX, WangY, et al. . MRI and ultrasonography detection of cervical lymph node metastases in differentiated thyroid carcinoma before reoperation. Am J Transl Res, 2014, 6(2): 147-154 PMID: 24489994 PMCID: 3902225

[24] XiangY, LinK, DongS, et al. . Prediction of central lymph node metastasis in 392 patients with cervical lymph node-negative papillary thyroid carcinoma in Eastern China. Oncol Lett, 2015, 10(4): 2559-2564 PMID: 26622889 PMCID: 4580067

[25] ZhangL, LiuZ, LiuY, et al. . The clinical prognosis of patients with cN0 papillary thyroid microcarcinoma by central neck dissection. World J Surg Oncol, 2015, 13: 138 PMID: 25889385 PMCID: 4443599

[26] NeslihanK, BurakE, YesimS, et al. . BRAFV600E mutation: has it a role in cervical lymph node metastasis of papillary thyroid cancer. Eur Thyroid J, 2016, 5(3): 195-200

[27] ChangSH, LiuCH, ConwayR, et al. . Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA, 2004, 101(2): 591-596 PMID: 14688410

[28] SaharinenP, EklundL, PulkkiK, et al. . VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med, 2011, 17(7): 347-362 PMID: 21481637